We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
19
Jun 2026
A new study published in JMIR Serious Games suggests that some video games may do more than entertain-they may also help adults cope with loneliness and build emotional resilience.
19
Jun 2026
Discover how AI, automation, and next-generation DMTA workflows are accelerating drug discovery with expert insights from TTP leaders.
19
Jun 2026
A new gene therapy has been used to successfully treat a deadly childhood liver disease using mice that model this disease by researchers at UCL and Great Ormond Street Hospital.
19
Jun 2026
The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), today announced that the Ann Theodore Foundation Learning Opportunities in Medicine and Sarcoidosis (ATF-LOMAS) grant program has committed its first cycle of funding, totaling US$600,000 to early-career faculty conducting biomedical research in sarcoidosis.